Τίτλος:
Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn's disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Συγγραφείς:
Rizos, E.D.
Antonogiannaki, E.-M.
Chatzidakis, A.
Kallieri, M.
Tsilogianni, Z.
Manali, E.D.
Economopoulos, N.
Triantafyllou, K.
Papiris, S.A.
Polymeros, D.
Περιοδικό:
European Journal of Gastroenterology and Hepatology
Αριθμός / τεύχος:
1S Suppl 1
DOI:
10.1097/MEG.0000000000002197
